|
1. J. Ferlay, H. R. Shin, F. Bray, D. Forman, C. Mathers, and D. M. Parkin, “Cancer Incidence and Mortality Worldwide: IARC,” Globocan 2008, IARC CancerBase http://globocan. iarc.fr . 2. Z. Hu, C. Fan, D. S. Oh et al., “The molecular portraits of breast tumors are conserved across microarray platforms,” BMC Genomics, vol. 7, article no. 96, 2006. 3. B. P. Zhou,M.C.T.Hu, S. A. Miller et al., “HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF- κB pathway,” Journal of Biological Chemistry, vol. 275, no. 11, pp. 8027–8031, 2000. 4. Florescu, A., et al., Immune therapy for breast cancer in 2010-hype or hope? Curr Oncol, 2011. 18(1): p. e9-e18. 5. R, D., et al., - EGFR over-expression and activation in high HER2, ER negative breast cancer cell. Breast Cancer Res Treat, 2010. 122(3): p. 685-97. 6. Kong, A., et al., HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells. PLoS One, 2008. 3(8): p. e2881. 7. Coussens, L., et al., Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science, 1985. 230(4730): p. 1132-1139. 8. M. A. Olayioye, R. M. Neve, H. A. Lane, and N. E. Hynes,“The ErbB signaling network: receptor heterodimerization indevelopment and cancer,” EMBO Journal, vol. 19, no. 13, pp.3159–3167, 2000. 9. P. R. Pohlmann, I. A.Mayer, and R.Mernaugh, “Resistance to trastuzumab in breast cancer,” Clinical Cancer Research, vol.15, no. 24, pp. 7479–7491, 2009 10. Stern, D.F., ErbBs in mammary development. Exp Cell Res, 2003. 284(1): p. 89-98. 11. Jackson-Fisher, A.J., et al., ErbB2 is required for ductal morphogenesis of the mammary gland. Proc Natl Acad Sci U S A, 2004. 101(49): p. 17138-43. 12. Cortes, J., et al., HER2 and hormone receptor-positive breast cancer[mdash]blocking the right target. Nat Rev Clin Oncol, 2011. 8(5): p. 307-311.
13. Takanami, I., Increased expression of integrin-linked kinase is associated with shorter survival in non-small cell lung cancer. BMC Cancer, 2005. 5: p. 1. 14. Sawai, H., et al., Integrin-linked kinase activity is associated with interleukin-1 alpha-induced progressive behavior of pancreatic cancer and poor patient survival. Oncogene, 2006. 25(23): p. 3237-46. 15. Seidman, A, et al. (2002). "Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience". Journal of Clinical Oncology 20 (5): 1215–1221. doi:10.1200/JCO.20.5.1215. PMID 11870163. 16. Zeglinski, M., Ludke, A., Jassal, D. S. &; Singal, P. K. Trastuzumab-induced cardiac dysfunction: A 'dual-hit'. Exp. Clin. Cardiol. 16, 70-74 (2011) 17. Bravou, V., et al., Integrin-linked kinase (ILK) expression in human colon cancer. Br J Cancer, 2003. 89(12): p. 2340-1. 18. Li, Y., Role for integrin-linked kinase in mediating tubular epithelial to mesenchymal transition and renal interstitial fibrogenesis. Journal of Clinical Investigation, 2003. 112(4): p. 503-516. 19. Oloumi, A., S. Syam, and S. Dedhar, Modulation of Wnt3a-mediated nuclear beta-catenin accumulation and activation by integrin-linked kinase in mammalian cells. Oncogene, 2006. 25(59): p. 7747-57. 20. Persad, S., et al., Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc Natl Acad Sci U S A, 2000. 97(7): p. 3207-12. 21. A. M. V. Petit, J. Rak, M. C. Hung et al., “Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors,” American Journal of Pathology, vol. 151, no. 6, pp. 1523–1530, 1997. 22. A. D. Seidman, D. Berry, C. Cirrincione et al., “Randomizedphase III trial of weekly compared with every-3-weekspaclitaxel for metastatic breast cancer, with trastuzumab forall HER-2 overexpressors and random assignment to trastuzumabor not in HER-2 nonoverexpressors: final results ofcancer and leukemia group B protocol 9840,” Journal ofClinical Oncology, vol. 26, no. 10, pp. 1642–1649, 2008. 23. C. L. Vogel, M. A. Cobleigh, D. Tripathy et al., “Efficacy andsafety of trastuzumab as a single agent in first-line treatmentof HER2-overexpressing metastatic breast cancer,” Journal ofClinical Oncology, vol. 20, no. 3, pp. 719–726, 2002. 24. Y. Nagata, K. H. Lan, X. Zhou et al., “PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients,” Cancer Cell, vol. 6, no. 2, pp. 117–127, 2004. 25. K. Berns, H. M. Horlings, B. T. Hennessy et al., “A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer,” Cancer Cell, vol. 12, no. 4, pp. 395–402, 2007. 26. M. Scaltriti, F. Rojo, A. Oca˜na et al., “Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer,” Journal of the National Cancer Institute, vol. 99, no. 8, pp. 628–638, 2007. 27. Sliva, D., Ganoderma lucidum (Reishi) in cancer treatment. Integr Cancer Ther, 2003. 2(4): p. 358-64. 28. Chou, T.C. Theoretical basis, experiment design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58, 621-681 (2006). 29. Rita Nahta, Francisco J, Esteva. Herceptin: mechanisms of action and resistance, Cancer Letters 232 (2006) 123–138 30. D. Yee, The insulin-like growth factor system as a treatmenttarget in breast cancer, Semin. Oncol. 29 (2002) 86–95. 31. Y.H. Lu, X.L. Zi, Y.H. Zhao, D. Mascarenhas, M. Pollak,Insulin-like growth factor-I receptor signaling and resistanceto trastuzumab (Herceptin), J. Natl Cancer Inst. 93 (2001)1852–1857. 32. Miyagawa K (2008). Clinical relevance of the homologous recombination machinery in cancer therapy. Cancer Sci 99, 187–194.
33. Dhillon J, Astanehe A, Lee C, Fotovati A, Hu K, Dunn SE. (2010). The expression of activated Y-box binding protein-1 serine 102 medites trastuzumab resistance in breast cancer cells by increasing CD44+ cells. Oncogene 29:6294-6300. 34. Obara S, Nakata M, Takeshima H, Katagiri H, Asano T, Oka Y et al. (2004). Integrin-linked kinase (ILK) regulation of the cell viability in PTEN mutant glioblastoma and in vitro inhibition by the specific COX-2 inhibitor NS-398. Cancer Lett 208: 115–122. 35. Graff JR, Deddens JA, Konicek BW, Colligan BM, Hurst BM, Carter HW et al. (2001). Integrin-linked kinase expression increases with prostate tumor grade. Clin Cancer Res 7: 1987–1991. 36. Sawai H, Okada Y, Funahashi H, Matsuo Y, Takahashi H, Takeyama H et al. (2006). Integrin-linked kinase activity is associated with interleukin-1 alpha-induced progressive behavior of pancreatic cancer and poor patient survival. Oncogene 25: 3237–3246. 37. Kumar AS, Naruszewicz I, Wang P, Leung-Hagesteijn C, Hannigan GE. (2004). ILKAP regulates ILK signaling and inhibits anchorageindependent growth. Oncogene 23: 3454–3461. 38. Li Y, Yang J, Dai C, Wu C, Liu Y. (2003). Role for integrin-linked kinase in mediating tubular epithelial to mesenchymal transition and renal interstitial fibrogenesis. J Clin Invest 112: 503–516. 39. D.J. Slamon, W. Godolphin, L.A. Jones, J.A. Holt, S.G. Wong, D.E. Keith, et al., Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, Science 244 (1989) 707–712. 40. C.T. Guy, M.A. Webster, M. Schaller, T.J. Parsons, R.D. Cardiff, W.J. Muller, Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease, Proc. Natl Acad. Sci. USA 89 (1992) 10578–10582. 41. F.J. Esteva, V. Valero, D. Booser, L.T. Guerra, J.L. Murray, L. Pusztai, et al., Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer, J. Clin. Oncol. 20 (2002) 1800–1808.
|